title: A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
abstract: Dopamine can induce fascinating, complex human behavioral states, including disinhibition, euphoria, or elaborate stereotypies, whereas dopamine deficiency can cause anxiety or sadness. Limited data suggest that these phenomena may involve dysfunction of orbital frontal cortex, cingulate cortex, or ventral striatum. The dopamine D3 receptor (D3R) has an anatomic distribution that suggests it could mediate these effects, but almost no data directly demonstrate the regional functional effects of D3R activation. We used quantitative positron emission tomography (PET), [15O]water, and the D3-preferring dopamine agonist pramipexole to identify D3-mediated regional cerebral blood flow (rCBF) responses in living primates. We studied seven normal baboons ventilated with 70% nitrous oxide, and analyzed results voxelwise in a common atlas space. At clinically relevant doses, pramipexole produced statistically robust decreases in rCBF in bilateral orbitofrontal cortex, thalamus, operculum, posterior and anterior (subgenual) cingulate cortex, and insula (in decreasing order of significance). Cortical areas related to movement were relatively unaffected, and rCBF did not change in cerebellum or visual cortex. The dose-response curve and duration of pramipexole's effects suggest that these rCBF responses indicate functional effects of a D3-preferring agonist. A D2-preferring agonist studied under the same conditions produced a quantitatively different pattern of responses. We conclude that a dopamine D3 receptor agonist preferentially affects brain activity in prefrontal and limbic cortex, and speculate that dopamine's effects on these regions via D3Rs may mediate some of the known psychiatric complications of dopamine deficiency or excess.
authors.affiliation: Departments of Psychiatry, School of Medicine, Washington University, 660 South Euclid Avenue, St. Louis, MO 63110, USA. kevin@npg.wustl.edu
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Black
authors.forename: Tamara
authors.initials: T
authors.lastname: Hershey
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Koller
authors.forename: Tom O
authors.initials: TO
authors.lastname: Videen
authors.forename: Mark A
authors.initials: MA
authors.lastname: Mintun
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Price
authors.forename: Joel S
authors.initials: JS
authors.lastname: Perlmutter
mesh_terms: D000818:Animals; D052160:Benzothiazoles; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D008032:Limbic System / Q000187:drug effects* / Q000502:physiology; D001523:Mental Disorders / Q000209:etiology*; D019964:Mood Disorders / Q000209:etiology*; D010215:Papio; D000077487:Pramipexole; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D050637:Receptors, Dopamine D3; D013844:Thiazoles / Q000494:pharmacology; D014055:Tomography, Emission-Computed
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013844:Thiazoles; D000077487:Pramipexole; D004298:Dopamine